Our coverage of SIX-listed biotechnology companies currently includes:
Addex Therapeutics Ltd (ADXN)
Basilea Pharmaceutica AG (BSLN)
Cosmo Pharmaceuticals NV (COPN)
Kuros Biosciences AG (KURN)
Newron Pharmaceuticals SpA (NWRN)
Relief Therapeutics Holding SA (RLF)
Santhera Pharmaceuticals AG (SANN)
Spexis AG (SPEX)
Valuation Reports of these companies can be downloaded free of charge in the Research Section below by accepting the Research Disclaimer.
valuationLAB AG accepts no liability for direct or indirect losses incurred as a result of accessing or using this site and the information published on it.
All data and information provided on the valuationLAB site is for informational purposes only, and no mention of a particular company or security herein constitutes a recommendation to buy, sell, or hold that or any other security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
The content of this website is not intended for distribution to retail investors. Research reports on this website are not directed to or intended for distribution to or use by any person or entity in any jurisdiction where such distribution, publication or use would be unlawful.
The information on this site is intended for qualified investors pursuant to Art 10.3 and 10.4 of the Collective Investment Schemes Act (CISA) and contain information on investments that may only be offered to such investors and may not be publicly distributed. The sale and distribution of the securities described on this website are only allowed in certain jurisdictions. In others, the sale and distribution of such products may be forbidden.
If you are deemed a qualified investor pursuant to Financial Market Supervisory Authority (FINMA) Art. 10 Para 3 CISA (FINMA- Circ. 08/8 Public advertising collective investment schemes) and Art.10.4, please click on “I Agree, ENTER RESEARCH” above if you wish to enter the Research section.
By selecting this category, you confirm that you meet one or more of the definition criteria for qualified investors, that you have read the notice regarding the content of the pages reserved for such investors, and accept the foregoing limitations.